ArticleBMC veterinary research2025
Sodium-glucose transporters SGLT1 and SGLT2 in equine renal, hepatic and pancreatic tissue.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The effect of ertugliflozin on serum insulin and glucose in healthy horses receiving dexamethasone.Journal of veterinary internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin dysregulation is a hallmark of equine metabolic syndrome (EMS), and in recent years, pharmacological treatment with sodium-dependent glucose transporter 2 inhibitors (SGLT2i) have shown promise in reducing the risk of hyperinsulinemia-associated laminitis in horses diagnosed with EMS. In humans and laboratory animals, this transporter protein is responsible for the majority of renal tubular glucose reabsorption, however, the presence of this and the related sodium-dependent glucose transporter 1 (SGLT1) have not yet been studied in equine kidneys. Additionally, studies in humans and laboratory animals have documented the presence of SGLT1 and SGLT2 also in hepatic and pancreatic tissue, which may explain extra-renal treatment effects of SGLT2i. Since the specificity towards SGLT2 and SGLT1 differ between the various SGLT2i drugs currently in use in horses, investigating SGLT2 and SGLT1 protein expression in equine tissues may help understanding potential differences in treatment effect and/or side effect profile between substances. The objective of this study was therefore to evaluate the presence of SGLT2 and SGLT1 in equine kidneys, liver and pancreas.
resultsTissue samples from ten healthy Norwegian/Swedish Coldblood Trotters were collected. Using immunohistochemistry with antibodies raised against human SGLT1 and SGLT2, a strong SGLT2 antibody signal was present in the apical membranes of epithelial cells in the cortical labyrinth of the kidney, while SGLT1 positive cells were predominantly found in medullary rays. Both of these results concur with those in humans and rats. Using electron microscopy, ultrastructural localisation of positive SGLT2 antibody signal was confirmed to the microvilli of tubular epithelial cells. Positive SGLT2 signal was also detected in periportal hepatocytes and in cells within islet of Langerhans in the endocrine pancreas. Positive SGLT1 signal was seen in cholangiocytes in the portal areas of the liver, and in Kuppfer cells.
conclusionsThe present study confirms presence of SGLT2 and SGLT1 in the equine kidney, localized to the proximal tubule. Also, presence of SGLT2 in the liver and pancreas, suggest that SGLT2i may have both renal and extrarenal effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.